A- A A+

The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance. 

Meyers-Pantele SA, Mittal ML, Jain S, Sun S, Rammohan I, Fairbairn N, Milloy MJ, DeBeck K, Hayashi K, Werb D. 

Subst Abuse Treat Prev Policy. 2022 May 19;17(1):39. doi: 10.1186/s13011-022-00470-6. PMID: 35590419; PMCID: PMC9118611.


The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review. 

Jordan CG, Kennalley AL, Roberts AL, Nemes KM, Dolma T, Piper BJ. 

Pharmacy (Basel). 2022 Apr 19;10(3):48. doi: 10.3390/pharmacy10030048. PMID: 35645327; PMCID: PMC9149874.


What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings. 

Hooker SA, Sherman MD, Lonergan-Cullum M, Nissly T, Levy R. 

J Subst Abuse Treat. 2022 May 20:108804. doi: 10.1016/j.jsat.2022.108804. Epub ahead of print. PMID: 35643586.



What factors influence retention in buprenorphine and methadone treatment?

Medication treatments for opioid use disorder are effective lifesaving therapies, and studies suggest that longer treatment durations result in better patient outcomes (e.g., reduced overdose death risk, less use of ambulatory care services). Identifying the factors that best predict retention can ultimately help us develop and roll out strategies to enhance retention. In this study, the researchers examined which factors were the strongest predictors of medication retention in an Australian sample. (Recovery Research Institute, USA, 22.04.2022)


Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials. 

Lim J, Farhat I, Douros A, Panagiotoglou D (2022) 

PLoS ONE 17(3): e0266142. doi.org/10.1371/journal.pone.0266142


Review of medication-assisted treatment for opioid use disorder. 

Ghanem N, Dromgoole D, Hussein A, Jermyn RT. 

J Osteopath Med. 2022 Mar 14. doi: 10.1515/jom-2021-0163. Epub ahead of print. PMID: 35285220.


Update Suchtmedizin: Neue Optionen in der Substitution

Zu Substitution stehen heute zahlreiche Substanzen und Darreichungsformen zur Verfügung. In den letzten Jahren sind insbesondere retardierte Präparate hinzu gekommen, so dass mittlerweile eine auf individuelle Bedürfnisse zugeschnittene Substitution möglich ist. (Richard Kamm, München, Praxis Concept München, in: hiv&more 4/2021


Interim opioid agonist treatment for opioid addiction: a systematic review. 

Samsó Jofra L, Puig T, Solà I, Trujols J. 

Harm Reduct J. 2022 Jan 29;19(1):7. doi: 10.1186/s12954-022-00592-x. PMID: 35090475; PMCID: PMC8800211.


Opioid agonist treatment for self-harm and suicide prevention

Nestadt, Paul S et al.

The Lancet Psychiatry, Volume 9, Issue 2, 100 - 101 



A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder. 

Chawar C, Hillmer A, Sanger S, D'Elia A, Panesar B, Guan L, Xie DX, Bansal N, Abdullah A, Kapczinski F, Pare G, Thabane L, Samaan Z. 

Addict Sci Clin Pract. 2021 Nov 27;16(1):70. doi: 10.1186/s13722-021-00278-y. PMID: 34838141; PMCID: PMC8627063.


Cost-effectiveness of Treatments for Opioid Use Disorder. 

Fairley M, Humphreys K, Joyce VR, et al. 

JAMA Psychiatry. 2021;78(7):767–777. doi:10.1001/jamapsychiatry.2021.0247


Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone. 

Agin-Liebes G, Huhn AS, Strain EC, Bigelow GE, Smith MT, Edwards RR, Gruber VA, Tompkins DA.

Drug Alcohol Depend. 2021 Sep 1;226:108869. doi: 10.1016/j.drugalcdep.2021.108869. Epub 2021 Jun 25. PMID: 34216862.


High-dose intravenous hydromorphone for patients who use opioids in the hospital setting: time to reduce the barriers.

Labonté, L.E., Young, S. 

Harm Reduct J 18, 87 (2021). doi.org/10.1186/s12954-021-00533-0


Treatment of opium addiction in persian medicine: A review study. 

Kamali M, Kamali H, Doustmohammadi M, Sheikhbardsiri H, Moghadari M. 

J Educ Health Promot. 2021 May 20;10:157. doi: 10.4103/jehp.jehp_5_21. PMID: 34222532; PMCID: PMC8224515.


USA. TIP 63: Medications for Opioid Use Disorder - Executive Summary

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, 10.08.2021)


USA. TIP 63: Medications for Opioid Use Disorder - For Healthcare and Addiction Professionals, Policymakers, Patients, and Families - Full Document

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, Juli 2021)


Opium tincture-assisted treatment for opioid use disorder: A systematic review. 

Noroozi A, Kebriaeezadeh A, Mirrahimi B, Armoon B, Ahounbar E, Narenjiha H, Salehi M, Karamouzian M. 

J Subst Abuse Treat. 2021 Jun 4;129:108519. doi: 10.1016/j.jsat.2021.108519. Epub ahead of print. PMID: 34119894.



A novel maintenance therapeutic for Opioid Use Disorder. 

Youngblood B, Li K, Gehlert DR, Medina JC, Schwartz N.

J Pharmacol Exp Ther. 2021 May 19:JPET-AR-2020-000214. doi: 10.1124/jpet.120.000214. Epub ahead of print. PMID: 34011529.


Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. 

Santo T, Clark B, Hickman M, et al. 

JAMA Psychiatry. Published online June 02, 2021. doi:10.1001/jamapsychiatry.2021.0976


Opioid Agonist Therapy reduces mortality risk among people with opioid dependence

A new global review has found that receiving Opioid Agonist Therapy (OAT) is associated with lower risk of multiple causes of death among people with opioid dependence. (University of Bristol, UK, 02.06.2021)


Opioid Agonist Therapy (OAT) associated with lower risk of multiple causes of death for people with opioid dependence

A new global review has found that receiving Opioid Agonist Therapy (OAT) is associated with lower risk of multiple causes of death among people with opioid dependence. 

The review found that people with opioid dependence were less likely to experience overdose-related, suicide, alcohol-related, cancer, and cardiovascular-related mortality while receiving OAT. 

Researchers from the National Drug and Alcohol Research Centre (NDARC) at UNSW Sydney, University of Bristol and several other global institutions reviewed the relationship between OAT and mortality across type of drug, setting and participant groups from over 700,000 participants, which is six times the number of any other previous review. (National Drug and Alcohol Research Centre (NDARC), Australien, 03.06.2021)


New Approaches in Drug Dependence: Opioids. 

Mielau J, Vogel M, Gutwinski S, Mick I. 

Curr Addict Rep. 2021 May 26:1-8. doi: 10.1007/s40429-021-00373-9. Epub ahead of print. PMID: 34055568; PMCID: PMC8149259.


Quality of Life in Opioid Replacement Therapy: A Naturalistic Cross-Sectional Comparison of Methadone/Levomethadone, Buprenorphine, and Diamorphine Patients. 

Guillery SPE, Hellweg R, Kronenberg G, Bohr U, Kunte H, Enge S. 

Eur Addict Res. 2021 Mar 30:1-10. doi: 10.1159/000514192. Epub ahead of print. PMID: 33784698.


Berlin. 15 Jahre Erhebungen zum sogenannten „Beikonsum“ - Was und wieviel konsumieren unsere Klienten* neben ihrem verschriebenen Substitutionsmedikament?

2005 ging es los – erstmals fragten wir das „Handlungswissen“ derjenigen ab, die im Notdienst Berlin e.V. die psychosoziale Betreuung von Menschen durchführen, welche sich in einer ärztlichen Substitutionsbehandlung befinden. Im Fokus unserer standardisierten Fragebögen stand und steht der zusätzliche Konsum psychoaktiver Substanzen neben dem jeweils verwendeten Substitutionsmedikament.

Die Befragung, die jährlich über einen gesamten Monat in allen relevanten Einrichtungen durchgeführt wird, zeigt längs- und quervalidierte Massendaten in einzigartiger Qualität, Umfänglichkeit und Differenziertheit. Über nun mittlerweile 15 Jahre sehen wir kurz-, mittel- und langfristige Veränderungen von Konsummustern, differenziert nach Alter, Geschlecht und Behandlungsdauer. Das ermöglicht es uns, fundierter und gezielter mit angemessenen Interventionen zu reagieren, wo immer dies erforderlich ist. (Notdienst für Suchtmittelgefährdete und -abhängige Berlin e.V., 16.03.2021)


When Physical and Social Pain Coexist: Insights Into Opioid Therapy

Mark D. Sullivan, Jane C. Ballantyne

The Annals of Family Medicine Jan 2021, 19 (1) 79-82; DOI: 10.1370/afm.2591 


Opioid agonist and antagonist use and the gut microbiota: associations among people in addiction treatment. 

Gicquelais RE, Bohnert ASB, Thomas L, Foxman B. 

Sci Rep. 2020 Nov 10;10(1):19471. doi: 10.1038/s41598-020-76570-9. PMID: 33173098; PMCID: PMC7655955.


Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study. 

Ivsins A, Boyd J, Mayer S, Collins A, Sutherland C, Kerr T, McNeil R. 

Drug Alcohol Depend. 2020 Nov 1;216:108202. doi: 10.1016/j.drugalcdep.2020.108202. Epub 2020 Sep 15. PMID: 32948372; PMCID: PMC7490624.


Opioid-Agonisten-Therapie bei Opioidabhängigkeit [Opioid Agonist Therapy (OAT) for opioid dependency

Köck P, Strasser J. 

Ther Umsch. 2020;77(1):29-36. German. doi: 10.1024/0040-5930/a001148. PMID: 32486990.



Betäubungsmittel im Fokus: Sonderfall Substitutionstherapie 

Verordnungen von Substitutionsmitteln sind ein Fall für sich. Bei der Bearbeitung eines solchen Rezepts gilt es zahlreiche Regelungen zu beachten. Der siebte Teil der PZ-Serie »Betäubungsmittel im Fokus« beleuchtet die verschiedenen Therapieformen und deren Besonderheiten. (PZ – Pharmazeutische Zeitung, 05.10.2020)


Hospital Initiated Injectable Opioid Agonist Therapy for the Treatment of Severe Opioid Use Disorder: A Case Series

Brar R, Fairbairn N, Colizza K, Ryan A, Nolan S. 

[published online ahead of print, 2020, Aug 4]. J Addict Med. 2020;10.1097/ADM.0000000000000713. doi:10.1097/ADM.0000000000000713